679 related articles for article (PubMed ID: 16412990)
1. Effects of rimonabant, a selective cannabinoid CB1 receptor antagonist, in a rat model of Parkinson's disease.
González S; Scorticati C; García-Arencibia M; de Miguel R; Ramos JA; Fernández-Ruiz J
Brain Res; 2006 Feb; 1073-1074():209-19. PubMed ID: 16412990
[TBL] [Abstract][Full Text] [Related]
2. Cannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null mice.
González S; Mena MA; Lastres-Becker I; Serrano A; de Yébenes JG; Ramos JA; Fernández-Ruiz J
Brain Res; 2005 Jun; 1046(1-2):195-206. PubMed ID: 15882845
[TBL] [Abstract][Full Text] [Related]
3. Enhanced striatal glutamate release after the administration of rimonabant to 6-hydroxydopamine-lesioned rats.
García-Arencibia M; Ferraro L; Tanganelli S; Fernández-Ruiz J
Neurosci Lett; 2008 Jun; 438(1):10-3. PubMed ID: 18457923
[TBL] [Abstract][Full Text] [Related]
4. CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats.
Rubio M; Fernández-Ruiz J; de Miguel R; Maestro B; Michael Walker J; Ramos JA
Neuropharmacology; 2008 May; 54(6):976-88. PubMed ID: 18371990
[TBL] [Abstract][Full Text] [Related]
5. The CB(1) antagonist rimonabant is adjunctively therapeutic as well as monotherapeutic in an animal model of Parkinson's disease.
Kelsey JE; Harris O; Cassin J
Behav Brain Res; 2009 Nov; 203(2):304-7. PubMed ID: 19414037
[TBL] [Abstract][Full Text] [Related]
6. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
[TBL] [Abstract][Full Text] [Related]
7. Intranigral administration of substance P receptor antagonist attenuated levodopa-induced dyskinesia in a rat model of Parkinson's disease.
Yang X; Zhao H; Shi H; Wang X; Zhang S; Zhang Z; Zu J; Zhang W; Shen X; Cui G; Hua F
Exp Neurol; 2015 Sep; 271():168-74. PubMed ID: 26001615
[TBL] [Abstract][Full Text] [Related]
8. Loss of cannabinoid CB1 receptor expression in the 6-hydroxydopamine-induced nigrostriatal terminal lesion model of Parkinson's disease in the rat.
Walsh S; Mnich K; Mackie K; Gorman AM; Finn DP; Dowd E
Brain Res Bull; 2010 Apr; 81(6):543-8. PubMed ID: 20097273
[TBL] [Abstract][Full Text] [Related]
9. Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ⁹-THCV in animal models of Parkinson's disease.
García C; Palomo-Garo C; García-Arencibia M; Ramos J; Pertwee R; Fernández-Ruiz J
Br J Pharmacol; 2011 Aug; 163(7):1495-506. PubMed ID: 21323909
[TBL] [Abstract][Full Text] [Related]
10. Effects of levodopa on endocannabinoid levels in rat basal ganglia: implications for the treatment of levodopa-induced dyskinesias.
Ferrer B; Asbrock N; Kathuria S; Piomelli D; Giuffrida A
Eur J Neurosci; 2003 Sep; 18(6):1607-14. PubMed ID: 14511339
[TBL] [Abstract][Full Text] [Related]
11. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence.
de Lago E; de Miguel R; Lastres-Becker I; Ramos JA; Fernández-Ruiz J
Brain Res; 2004 May; 1007(1-2):152-9. PubMed ID: 15064146
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the antiparkinsonism and neuroprotective effects of hydrogen sulfide in acute 6-hydroxydopamine-induced animal model of Parkinson's disease: behavioral, histological and biochemical studies.
Sarukhani M; Haghdoost-Yazdi H; Sarbazi Golezari A; Babayan-Tazehkand A; Dargahi T; Rastgoo N
Neurol Res; 2018 Jul; 40(7):523-531. PubMed ID: 29726751
[TBL] [Abstract][Full Text] [Related]
13. UCM707, an inhibitor of the anandamide uptake, behaves as a symptom control agent in models of Huntington's disease and multiple sclerosis, but fails to delay/arrest the progression of different motor-related disorders.
de Lago E; Fernández-Ruiz J; Ortega-Gutiérrez S; Cabranes A; Pryce G; Baker D; López-Rodríguez M; Ramos JA
Eur Neuropsychopharmacol; 2006 Jan; 16(1):7-18. PubMed ID: 16006105
[TBL] [Abstract][Full Text] [Related]
14. Characterization of the striatal 6-OHDA model of Parkinson's disease in wild type and alpha-synuclein-deleted mice.
Alvarez-Fischer D; Henze C; Strenzke C; Westrich J; Ferger B; Höglinger GU; Oertel WH; Hartmann A
Exp Neurol; 2008 Mar; 210(1):182-93. PubMed ID: 18053987
[TBL] [Abstract][Full Text] [Related]
15. Motor activity-induced dopamine release in the substantia nigra is regulated by muscarinic receptors.
Andersson DR; Björnsson E; Bergquist F; Nissbrandt H
Exp Neurol; 2010 Jan; 221(1):251-9. PubMed ID: 19944096
[TBL] [Abstract][Full Text] [Related]
16. Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors.
Espejo-Porras F; Fernández-Ruiz J; Pertwee RG; Mechoulam R; García C
Neuropharmacology; 2013 Dec; 75():155-63. PubMed ID: 23924692
[TBL] [Abstract][Full Text] [Related]
17. The combination of oral L-DOPA/rimonabant for effective dyskinesia treatment and cytological preservation in a rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
Gutiérrez-Valdez AL; García-Ruiz R; Anaya-Martínez V; Torres-Esquivel C; Espinosa-Villanueva J; Reynoso-Erazo L; Tron-Alvarez R; Aley-Medina P; Sánchez-Betancourt J; Montiel-Flores E; Avila-Costa MR
Behav Pharmacol; 2013 Dec; 24(8):640-52. PubMed ID: 24196024
[TBL] [Abstract][Full Text] [Related]
18. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
Pinna A; Tronci E; Schintu N; Simola N; Volpini R; Pontis S; Cristalli G; Morelli M
Neuropharmacology; 2010 Mar; 58(3):613-23. PubMed ID: 19951715
[TBL] [Abstract][Full Text] [Related]
19. Emotional, cognitive and neurochemical alterations in a premotor stage model of Parkinson's disease.
Tadaiesky MT; Dombrowski PA; Figueiredo CP; Cargnin-Ferreira E; Da Cunha C; Takahashi RN
Neuroscience; 2008 Oct; 156(4):830-40. PubMed ID: 18817851
[TBL] [Abstract][Full Text] [Related]
20. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
